Dry Eye Disease - Pipeline Insight, 2025
Description
DelveInsight’s, “Dry Eye Disease - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dry Eye Disease: Overview
Dry Eye Disease (DED) is a common ocular condition characterized by insufficient tear production or poor tear quality, leading to discomfort, inflammation, and potential damage to the eye surface. It results from a disruption in the tear film, which can be caused by aging, environmental factors, autoimmune diseases, or prolonged screen time. Symptoms include dryness, burning, redness, blurred vision, and a sensation of grittiness in the eyes. If left untreated, DED can impact daily activities and reduce overall quality of life. With an increasing prevalence worldwide, ongoing research focuses on advanced therapies to improve tear stability and alleviate symptoms.
DED has traditionally been classified into two categories: aqueous deficient and evaporative. These two categories, however, are not mutually exclusive, and numerous patients have a combination of these mechanisms of DED. Aqueous tear deficiency is characterized by inadequate tear production with predominant causes consisting of Sjogren Syndrome (primary or secondary); diseases, inflammation, and/or dysfunction of the lacrimal gland; obstruction of the lacrimal gland; and systemic drugs (i.e., decongestants, antihistamines, diuretics, beta-blockers, etc.) Evaporative dry eye is characterized by increased tear film evaporation and a deficiency in the lipid portion of the tear film. In this case, the quantity of tears produced is normal; however, the quality of tears causes excessive evaporation. This alteration is most frequently caused by meibomian gland dysfunction.
The most common cause of dry eye is a reduction of the aqueous layer through either decreased production from the lacrimal glands or evaporative loss secondary to dysfunction of the other two layers of the tear film. Aqueous production is known to decrease with age, and the immunoglobulin A and lysozyme levels associated with this tear layer also decrease.The posterior layer of the tear film is the mucin layer. Mucin is produced by the goblet cells located in the conjunctival tissue. The mucin layer allows optically smooth layering of the tear film, without break-up because of variable film density or evaporation. Reduction of the goblet cell density from inflammation or trauma can have devastating effects on tear film stability and produce severe dry eye symptoms, even in the presence of epiphora.
Treatment of dry eye syndrome is performed in a step-wise approach that may vary depending on the severity of the disease. Initial approaches include education about the condition, modification of the environment (eliminating direct high airflow/fans, reduced screen time, humidifier), identification and elimination of offending topical and systemic agents, topical ocular lubricants, and lid hygiene (warm compresses and lid scrubs), oral essential fatty acids.
The next step of treatment options includes preservative-free ocular lubricants, reversible punctal occlusion (punctal plugs), night-time ointment or moisture goggles, device-assisted heating and/or expression of the meibomian glands, intense pulsed light therapy, topical anti-inflammatory medications (corticosteroids, cyclosporine, lifitegrast), and oral antibiotics (macrolide or tetracycline).
""Dry Eye Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dry Eye Disease Emerging Drugs
Further product details are provided in the report……..
Dry Eye Disease: Therapeutic Assessment
This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:
Dry Eye Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs.
Dry Eye Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Dry Eye Disease: Overview
Dry Eye Disease (DED) is a common ocular condition characterized by insufficient tear production or poor tear quality, leading to discomfort, inflammation, and potential damage to the eye surface. It results from a disruption in the tear film, which can be caused by aging, environmental factors, autoimmune diseases, or prolonged screen time. Symptoms include dryness, burning, redness, blurred vision, and a sensation of grittiness in the eyes. If left untreated, DED can impact daily activities and reduce overall quality of life. With an increasing prevalence worldwide, ongoing research focuses on advanced therapies to improve tear stability and alleviate symptoms.
DED has traditionally been classified into two categories: aqueous deficient and evaporative. These two categories, however, are not mutually exclusive, and numerous patients have a combination of these mechanisms of DED. Aqueous tear deficiency is characterized by inadequate tear production with predominant causes consisting of Sjogren Syndrome (primary or secondary); diseases, inflammation, and/or dysfunction of the lacrimal gland; obstruction of the lacrimal gland; and systemic drugs (i.e., decongestants, antihistamines, diuretics, beta-blockers, etc.) Evaporative dry eye is characterized by increased tear film evaporation and a deficiency in the lipid portion of the tear film. In this case, the quantity of tears produced is normal; however, the quality of tears causes excessive evaporation. This alteration is most frequently caused by meibomian gland dysfunction.
The most common cause of dry eye is a reduction of the aqueous layer through either decreased production from the lacrimal glands or evaporative loss secondary to dysfunction of the other two layers of the tear film. Aqueous production is known to decrease with age, and the immunoglobulin A and lysozyme levels associated with this tear layer also decrease.The posterior layer of the tear film is the mucin layer. Mucin is produced by the goblet cells located in the conjunctival tissue. The mucin layer allows optically smooth layering of the tear film, without break-up because of variable film density or evaporation. Reduction of the goblet cell density from inflammation or trauma can have devastating effects on tear film stability and produce severe dry eye symptoms, even in the presence of epiphora.
Treatment of dry eye syndrome is performed in a step-wise approach that may vary depending on the severity of the disease. Initial approaches include education about the condition, modification of the environment (eliminating direct high airflow/fans, reduced screen time, humidifier), identification and elimination of offending topical and systemic agents, topical ocular lubricants, and lid hygiene (warm compresses and lid scrubs), oral essential fatty acids.
The next step of treatment options includes preservative-free ocular lubricants, reversible punctal occlusion (punctal plugs), night-time ointment or moisture goggles, device-assisted heating and/or expression of the meibomian glands, intense pulsed light therapy, topical anti-inflammatory medications (corticosteroids, cyclosporine, lifitegrast), and oral antibiotics (macrolide or tetracycline).
""Dry Eye Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.
This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dry Eye Disease Emerging Drugs
- AR-15512: Alcon
- SI-614: Seikagaku Corporation
- HU007: Huons
- A197: Aramis Biosciences
- INV 102: Invirsa, Inc.
- iVIEW 1001: IVIEW Therapeutics
Further product details are provided in the report……..
Dry Eye Disease: Therapeutic Assessment
This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dry Eye Disease
- There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. Phase III include, Alcon, Seikagaku Corporation, and Huons.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Dry Eye Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs.
Dry Eye Disease Report Insights
- Dry Eye Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dry Eye Disease drugs?
- How many Dry Eye Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dry Eye Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Alcon
- Seikagaku Corporation
- Huons
- Aramis Biosciences
- Invirsa, Inc.
- IVIEW Therapeutics
- Seinda Pharmaceutical
- Serentrix
- EyeD Pharma
- SELAGINE
- Theratome Bio
- Alchemedicine
- AR-15512
- SI-614
- HU007
- A197
- INV 102
- iVIEW 1001
- SY-201
- SER-114
- HydraD
- SLG-100
- Thera 102
- Dry eye disease therapeutic
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Dry Eye Disease: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dry Eye Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- AR-15512: Alcon
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- INV 102: Invirsa, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- iVIEW 1001: IVIEW Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dry Eye Disease Key Companies
- Dry Eye Disease Key Products
- Dry Eye Disease- Unmet Needs
- Dry Eye Disease- Market Drivers and Barriers
- Dry Eye Disease- Future Perspectives and Conclusion
- Dry Eye Disease Analyst Views
- Dry Eye Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
